ArticleFrontiers in oncology2026
Patient with AL amyloidosis with recurrent syncope as the first symptom: case report and literature review.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immunoglobulin light-chain (AL) amyloidosis is a rare systemic disease caused by the extracellular deposition of misfolded light chains. Nonspecific manifestations, especially those dominated by severe autonomic neuropathy, frequently delay diagnosis. Methods and results: A 68-year-old woman was admitted after five months of recurrent syncope. The clinical picture was dominated by refractory orthostatic hypotension, nausea and vomiting alternating with diarrhea and constipation, stocking-glove paresthesias, and proteinuria. Bone marrow examination showed the presence of clonal plasma cells with positive M protein, which was confirmed by the serum free light chain test. AL amyloidosis was diagnosed based on positive Congo red staining in renal biopsy specimens. The patient was enrolled in a daratumumab-based protocol combined with daratumumab, bortezomib, cyclophosphamide, and dexamethasone. After three cycles, complete hematological remission was achieved, and the autonomic nerve function improved gradually over the subsequent six months. Conclusion: This case and literature review suggest that AL amyloidosis should be considered whenever a patient presents with multisystem dysfunction dominated by autonomic nerve dysfunction. Although such presentations are associated with poor prognosis, prompt initiation of daratumumab-based therapy can produce rapid hematologic remission and clinically meaningful improvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.